When was MabSpace Biosciences founded?

MabSpace Biosciences was founded in 2013 and raised its 1st funding round 2 years after it was founded.

Where is MabSpace Biosciences located?

MabSpace Biosciences is headquartered in Hong Kong, China.

How many employees does MabSpace Biosciences have?

As of Apr 30, 2026, the latest employee count at MabSpace Biosciences is 13.

Is MabSpace Biosciences a funded company?

MabSpace Biosciences is a funded company, having raised a total of $55M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 28, 2015.

When was the latest funding round of MabSpace Biosciences?

MabSpace Biosciences' latest funding was a $***** Series B round on May 08, 2018, with participation from 3 investors. Its primary sector is Biopharma Outsourcing. In China, the Biopharma Outsourcing sector has seen $50.6M in funding in 2026 to date.

Where does MabSpace Biosciences rank among its competitors?

MabSpace Biosciences ranks 31st amongst 806 active competitors, of which 54 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Alloy Therapeutics, which secured $40M in Mar, 2026.

Who are the top competitors of MabSpace Biosciences?

MabSpace Biosciences' top competitors include Alloy Therapeutics, Maiva Pharma and Simulations Plus. Among them, Alloy Therapeutics secured the most recent funding round in March, 2026.

MabSpace Biosciences - 2026 Company Profile, Funding & Competitors

Company Details

MabSpace Biosciences is focused on the discovery and early development of antibody-based therapeutics. Using its proprietary immune tolerance breaking technology (IMTB), the company provides antibody discovery services to pharma companies. The company also provides in vitro and in vivo pharmacological profiling services. Their platform can be used for the development of antibodies for the treatment of cancer, metabolic disorders, and autoimmune diseases, among others.

Key Metrics

Founded Year

2013

Location

Hong Kong, China

Stage

Series B

Total Funding

$55M in 2 rounds

Latest Funding Round

Series B, May 08, 2018, $*****

Investors

Sequoia Capital & 2 more

Ranked

31^st among 806 active competitors

Employee Count

13 as on Apr 30, 2026

Similar Companies

Alloy Therapeutics & 827 more

View MabSpace Biosciences' full profile

MabSpace Biosciences has raised a total funding of $55M over 2 rounds. Its first funding round was on Oct 28, 2015. Its latest funding round was a Series B round on May 08, 2018 for $*****. 3 investors participated in its latest round. MabSpace Biosciences has 3 institutional investors.

Here is the list of recent funding rounds of MabSpace Biosciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 08, 2018	4444266	Series B	1168837	7852610	1984506	1677316
Oct 28, 2015	7400866	Series A	2146384	2894850	Lilly Asia Ventures	1843469

Access funding benchmarks and valuations. Sign up today!

View details of MabSpace Biosciences's funding rounds and investors

MabSpace Biosciences' employee count trend

MabSpace Biosciences has 13 employees as of Apr 26. Here is MabSpace Biosciences's employee count trend over the years:

Employee count trend for MabSpace Biosciences

Uncover MabSpace Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MabSpace Biosciences include Alloy Therapeutics, Maiva Pharma and Simulations Plus. Here is the list of Top 10 competitors of MabSpace Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alloy Therapeutics 2017, Lexington (United States), Series E	Provider of drug discovery services	$157M	8VC, Mubadala & 11 others	63/100
2nd	Maiva Pharma 1996, Hosur (India), Late Stage	Manufacturer of sterile injectables	$125M	Nhpea V Spear, Nano-Vista & 25 others	61/100
3rd	Simulations Plus 1996, Lancaster (United States), Public	Developer of modeling and simulation software and consulting services provider	-	FDA, NIH & 1 others	60/100
4th	Manifold Bio 2018, United States, Series A	Developer of tissue-targeted therapeutics using in vivo screening and AI design	$78.2M	Playground Global, Triatomic & 8 others	58/100
5th	VelaVigo 2021, Shanghai (China), Seed	Biotechnology research company developing biological drugs	$160M	Shunwei Capital, Panacea Venture & 17 others	54/100
6th	CILcare 2014, Montpellier (France), Series A	Service to develop health products aiming to diagnose, prevent, delay the progression or treat hearing loss and tinnitus	$42.3M	Shionogi, UVM Health & 4 others	53/100
7th	Biocom California 1995, San Diego (United States), Acquired	CRO focused on drug discovery & development for multiple therapeutic areas	-	-	51/100
8th	Syenex 2022, Chicago (United States), Series B	Developer of cell-specific delivery systems and programmable cell engineering payloads	$13.7M	AlleyCorp, KdT Ventures	51/100
9th	Viva Biotech 2006, Shanghai (China), Public	Research services focused on drug discovery and development	-	Temasek, ShenZhen GTJA Investment Group & 3 others	51/100
10th	Superluminal Medicines 2022, Boston (United States), Series A	Generative biological and chemical company focused on drug discovery	$158M	RA Capital Management, Insight Partners & 5 others	50/100
31st	MabSpace Biosciences 2013, Hong Kong (China), Series B	Platform for antibody discovery and development	$55M	Sequoia Capital, Sports bar king star & 1 others	41/100